Mirum Pharmaceuticals SG&A Expenses 2019-2024 | MIRM

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Mirum Pharmaceuticals sg&a expenses from 2019 to 2024. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Mirum Pharmaceuticals sg&a expenses from 2019 to 2024. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.

Related Stocks
Company Name	Market Cap
Amgen (AMGN)	$170.3B
Vertex Pharmaceuticals (VRTX)	$122B
Bristol Myers Squibb (BMY)	$112.5B
Gilead Sciences (GILD)	$111.9B
Regeneron Pharmaceuticals (REGN)	$91.4B
CSL (CSLLY)	$90.8B
GSK (GSK)	$76.6B
Argenex SE (ARGX)	$35.2B
Alnylam Pharmaceuticals (ALNY)	$34.8B
BioNTech SE (BNTX)	$25.9B
Biogen (BIIB)	$25.3B
Illumina (ILMN)	$24.5B
Moderna (MRNA)	$20.6B
BeiGene (BGNE)	$20.2B
Genmab (GMAB)	$15.1B
Incyte (INCY)	$14.6B
Exact Sciences (EXAS)	$13.1B
BioMarin Pharmaceutical (BMRN)	$12.6B
Insmed (INSM)	$12.2B
Bio-Techne Corp (TECH)	$12B
Vaxcyte (PCVX)	$11.9B
Sarepta Therapeutics (SRPT)	$11.7B
QIAGEN (QGEN)	$10B
Exelixis (EXEL)	$9.8B
Bio-Rad Laboratories (BIO.B)	$9.3B
Revolution Medicines (RVMD)	$9.3B
Intra-Cellular Therapies (ITCI)	$9.1B
Roivant Sciences (ROIV)	$8.5B
Legend Biotech (LEGN)	$8B
Repligen (RGEN)	$7.8B